

**Amendments to the Claims/Listing of Claims**

Please cancel claims 18, 20-28 and 30 without prejudice, and add new claims 31-55. This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Previously presented) A method for treating hyperplasia of non-cancerous cells in a blood vessel of a subject in need thereof, said method comprising administering to said subject an effective amount of a composition comprising an amorphous drug in nanoparticle form, coated with a protein, wherein said drug is selected from the group consisting of an antineoplastic, an antiproliferative, an angiogenesis inhibitor, and mixtures of any two or more thereof.
2. (Cancelled)
3. (Original) A method according to claim 1 wherein said hyperplasia occurs in blood vessel neointima.
4. (Original) A method according to claim 1 wherein said effective amount falls in the range of about 0.01 mg/kg up to about 15 mg/kg for a human subject.
5. (Original) A method according to claim 4 wherein said administration of said composition is repeated over a dosing cycle between 1 day and 6 months.
6. (Original) A method according to claim 1 wherein said composition is administered systemically.
7. (Original) A method according to claim 6 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.
8. (Original) A method according to claim 1 wherein said composition is administered before, during or after the occurrence of said hyperplasia.
9. (Previously presented) A method for reducing neointimal hyperplasia of non-cancerous cells associated with vascular interventional procedure(s) in a subject in need thereof,

said method comprising administering to said subject an effective amount of a composition comprising at least one amorphous drug in nanoparticle form, coated with a protein, wherein said drug is selected from the group consisting of an antineoplastic, an antiproliferative, an angiogenesis inhibitor, and mixtures of any two or more thereof.

10. (Original) A method according to claim 9 wherein said procedure comprises angioplasty, stenting or atherectomy.

11. (Original) A method according to claim 9 wherein said composition is administered before, during or after the vascular interventional procedure.

12. (Original) A method according to claim 9 wherein said composition is administered at the time of the vascular interventional procedure.

13. (Original) A method according to claim 9 wherein said effective amount falls in the range of about 0.01 mg/kg up to about 15 mg/kg for a human subject.

14. (Original) A method according to claim 13 wherein said administration of said composition is repeated over a dosing cycle between 1 day and 6 months.

15. (Original) A method according to claim 9 wherein said composition is administered systemically.

16. (Original) A method according to claim 9 wherein said composition is administered by deployment of a stent containing said at least one drug coated thereon.

17. (Previously presented) A method to reduce proliferation and cell migration in a subject undergoing a vascular interventional procedure, said method comprising systemically administering to said subject before, during or after said procedure, a formulation comprising (i) an amorphous drug in nanoparticle form, wherein said drug inhibits proliferation and cell migration, and (ii) a biocompatible protein, wherein said drug is coated with said protein, and wherein said drug is selected from the group consisting of an antineoplastic, an antiproliferative, an angiogenesis inhibitor, and mixtures of any two or more thereof.

18. – 28. (Cancelled)

29. (Previously presented) A method to reduce the toxicity of a drug that inhibits proliferation and migration of non-cancerous cells in a blood vessel, said method comprising combining said drug, in amorphous form and in the form of nanoparticles, with a biocompatible protein, wherein said drug is coated with said protein, wherein said drug is selected from the group consisting of an antineoplastic, an antiproliferative, an angiogenesis inhibitor, and mixtures of any two or more thereof.

30. (Cancelled)

31. (New) The method according to claim 1, wherein said drug is a taxane or analog or homolog thereof.

32. (New) The method according to claim 31, wherein said drug is a taxane.

33. (New) The method according to claim 32, wherein said taxane is paclitaxel.

34. (New) The method according to claim 1, wherein said drug is an epothilone or an analog or homolog thereof.

35. (New) The method according to claim 34, wherein said drug is an epothilone.

36. (New) The method according to claim 1, wherein said drug is a rapamycin or analog or homolog thereof.

37. (New) The method according to claim 36, wherein said drug is a rapamycin.

38. (New) The method according to claim 1, wherein said protein is albumin.

39. (New) The method according to claim 9, wherein said drug is a taxane or analog or homolog thereof.

40. (New) The method according to claim 39, wherein said drug is a taxane.

41. (New) The method according to claim 40, wherein said taxane is paclitaxel.

42. (New) The method according to claim 9, wherein said drug is an epothilone or an analog or homolog thereof.

43. (New) The method according to claim 42, wherein said drug is an epothilone.

44. (New) The method according to claim 9, wherein said drug is a rapamycin or analog or homolog thereof.

45. (New) The method according to claim 44, wherein said drug is a rapamycin.

46. (New) The method according to claim 9, wherein said protein is albumin.

47. (New) The method according to claim 17, wherein said drug is a taxane or analog or homolog thereof.

48. (New) The method according to claim 47, wherein said drug is a taxane.

49. (New) The method according to claim 48, wherein said taxane is paclitaxel.

50. (New) The method according to claim 17, wherein said drug is an epothilone or an analog or homolog thereof.

51. (New) The method according to claim 50, wherein said drug is an epothilone.

52. (New) The method according to claim 17, wherein said drug is a rapamycin or analog or homolog thereof.

53. (New) The method according to claim 52, wherein said drug is a rapamycin.

54. (New) The method according to claim 17, wherein said protein is albumin.

55. (New) The method according to claim 17, wherein said procedure comprises angioplasty, stenting or atherectomy.